ijms-logo

Journal Browser

Journal Browser

Histone Deacetylase Inhibitors in Health and Disease II

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 June 2020) | Viewed by 32437

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-12843 Prague 2, Czech Republic
Interests: biochemistry of carcinogenesis; xenobiochemistry; anticancer drugs; DNA-damaging drugs; epigenetic regulation; drug metabolism; drug targeting

Special Issue Information

Dear Colleagues,

Alteration of the histone proteins associated with DNA is a crucial process in the epigenetic regulation of DNA structure and function. Such epigenetic modifications, which play a fundamental role in human development, are also relevant for the initiation and progression of complex degenerative diseases and cancer. Histone deacetylases (HDACs) catalyze deacetylation of lysine residues leading to changes in expression of genes encoded by DNA linked to the histone molecule. HDAC inhibitors (HDACi) that consecutively regulate the activity of HDACs, have been extensively researched as therapeutics in psychiatry and neurology, in which a number of adverse outcomes are associated with aberrant HDAC function. Furthermore, HDACi have shown potential for the treatment of cardiac, neurodegenerative and inflammatory lung diseases. On the other hand, increased HDAC activity and expression was found in the development of different cancers, HDACi have also been shown to serve in, and have been approved for, potential cancer treatments, either on their own or in combination with other therapies, such as chemotherapy drugs. The mechanisms of action of HDAC inhibitors are based on changed gene expression and on alterations of histone or non-histone protein molecules through modulation of epigenetic and post-translational modifications, respectively. The shift to an enhanced acetylation/deacetylation status in a variety of tumors due to HDAC inhibition can result in modified gene expression, alteration of cell signaling processes, and can influence the proteasome system, activities of some protein kinases, as well as DNA demethylation. As a result, several biological processes, such as cell cycle arrest or apoptosis, are modified. In addition, HDAC inhibitors have antiangiogenic effects or can influence some cell signaling pathways, having a wide spectrum of effects. These findings indicate that HDACi play a crucial role, both in physiological development and the progression of many human diseases.

In this context, we would like to invite review and original articles that focus on understanding HDACi function in health and disease, especially in human cancer. In addition, articles associated with model disease systems, drug resistance, and therapy are requested for this Special Issue.

Prof. Dr. Marie Stiborova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Epigenetic regulations
  • Histone modifications
  • Deacetylases of histone lysines
  • Histone deacetylases as chromatin modifying enzymes
  • Histone deacetylase inhibitors
  • Role of histone deacetylase inhibitors in cancer, neurological diseases and immune disorders
  • Histone deacetylase inhibitors in human therapy

Published Papers (8 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 6577 KiB  
Article
The Distinct Function and Localization of METTL3/METTL14 and METTL16 Enzymes in Cardiomyocytes
by Orazio Angelo Arcidiacono, Jana Krejčí and Eva Bártová
Int. J. Mol. Sci. 2020, 21(21), 8139; https://doi.org/10.3390/ijms21218139 - 30 Oct 2020
Cited by 16 | Viewed by 4159
Abstract
It has become evident that epitranscriptome events, mediated by specific enzymes, regulate gene expression and, subsequently, cell differentiation processes. We show that methyltransferase-like proteins METTL3/METTL14 and N6-adenosine methylation (m6A) in RNAs are homogeneously distributed in embryonic hearts, and histone deacetylase (HDAC) [...] Read more.
It has become evident that epitranscriptome events, mediated by specific enzymes, regulate gene expression and, subsequently, cell differentiation processes. We show that methyltransferase-like proteins METTL3/METTL14 and N6-adenosine methylation (m6A) in RNAs are homogeneously distributed in embryonic hearts, and histone deacetylase (HDAC) inhibitors valproic acid and Trichostatin A (TSA) up-regulate METTL3/METTL14 proteins. The levels of METTL3 in mouse adult hearts, isolated from male and female animals, were lower in the aorta and pulmonary trunks when compared with atria, but METT14 was up-regulated in the aorta and pulmonary trunk, in comparison with ventriculi. Aging caused METTL3 down-regulation in aorta and atria in male animals. Western blot analysis in differentiated mouse embryonic stem cells (mESCs), containing 10–30 percent of cardiomyocytes, showed METTL3/METTL14 down-regulation, while the differentiation-induced increased level of METTL16 was observed in both wild type (wt) and HDAC1 depleted (dn) cells. In parallel, experimental differentiation in especially HDAC1 wild type cells was accompanied by depletion of m6A in RNA. Immunofluorescence analysis of individual cells revealed the highest density of METTL3/METTL14 in α-actinin positive cardiomyocytes when compared with the other cells in the culture undergoing differentiation. In both wt and HDAC1 dn cells, the amount of METTL16 was also up-regulated in cardiomyocytes when compared to co-cultivated cells. Together, we showed that distinct anatomical regions of the mouse adult hearts are characterized by different levels of METTL3 and METTL14 proteins, which are changed during aging. Experimental cell differentiation was also accompanied by changes in METTL-like proteins and m6A in RNA; in particular, levels and distribution patterns of METTL3/METTL14 proteins were different from the same parameters studied in the case of the METTL16 protein. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Graphical abstract

21 pages, 17993 KiB  
Article
In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)
by Annabelle Friedrich, Ann-Sophie Assmann, Lena Schumacher, Jana v. Stuijvenberg, Matthias U. Kassack, Wolfgang A. Schulz, Wynand P. Roos, Finn K. Hansen, Marc Pflieger, Thomas Kurz and Gerhard Fritz
Int. J. Mol. Sci. 2020, 21(13), 4747; https://doi.org/10.3390/ijms21134747 - 03 Jul 2020
Cited by 4 | Viewed by 3380
Abstract
Histone deacetylase inhibitors (HDACi) are already approved for the therapy of leukemias. Since they are also emerging candidate compounds for the treatment of non-malignant diseases, HDACi with a wide therapeutic window and low hazard potential are desirable. Here, we investigated a panel of [...] Read more.
Histone deacetylase inhibitors (HDACi) are already approved for the therapy of leukemias. Since they are also emerging candidate compounds for the treatment of non-malignant diseases, HDACi with a wide therapeutic window and low hazard potential are desirable. Here, we investigated a panel of 12 novel hydroxamic acid- and benzamide-type HDACi employing non-malignant V79 hamster cells as toxicology guideline-conform in vitro model. HDACi causing a ≥10-fold preferential cytotoxicity in malignant neuroblastoma over non-malignant V79 cells were selected for further genotoxic hazard analysis, including vorinostat and entinostat for control. All HDACi selected, (i.e., KSK64, TOK77, DDK137 and MPK77) were clastogenic and evoked DNA strand breaks in non-malignant V79 cells as demonstrated by micronucleus and comet assays, histone H2AX foci formation analyses (γH2AX), DNA damage response (DDR) assays as well as employing DNA double-strand break (DSB) repair-defective VC8 hamster cells. Genetic instability induced by hydroxamic acid-type HDACi seems to be independent of bulky DNA adduct formation as concluded from the analysis of nucleotide excision repair (NER) deficient mutants. Summarizing, KSK64 revealed the highest genotoxic hazard and DDR stimulating potential, while TOK77 and MPK77 showed the lowest DNA damaging capacity. Therefore, these compounds are suggested as the most promising novel candidate HDACi for subsequent pre-clinical in vivo studies. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Figure 1

15 pages, 1678 KiB  
Article
In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity
by Shana V. Stoddard, Kyra Dodson, Kamesha Adams and Davita L. Watkins
Int. J. Mol. Sci. 2020, 21(1), 219; https://doi.org/10.3390/ijms21010219 - 28 Dec 2019
Cited by 6 | Viewed by 2950
Abstract
Histone deacetylases (HDAC) are being targeted for a number of diseases such as cancer, inflammatory disease, and neurological disorders. Within this family of 18 isozymes, HDAC4 is a prime target for glioma, one of the most aggressive brain tumors reported. Thus, the development [...] Read more.
Histone deacetylases (HDAC) are being targeted for a number of diseases such as cancer, inflammatory disease, and neurological disorders. Within this family of 18 isozymes, HDAC4 is a prime target for glioma, one of the most aggressive brain tumors reported. Thus, the development of HDAC4 inhibitors could present a novel therapeutic route for glioma. In this work, molecular docking studies on cyclopropane hydroxamic acid derivatives identified five novel molecular interactions to the HDAC4 receptor that could be harnessed to enhance inhibitor binding. Thus, design guidelines for the optimization of potent HDAC4 inhibitors were developed which can be utilized to further the development of HDAC4 inhibitors. Using the developed guidelines, eleven novel cyclopropane hydroxamic acid derivatives were designed that outcompeted all original cyclopropane hydroxamic acids HDAC4 inhibitors studied in silico. The results of this work will be an asset to paving the way for further design and optimization of novel potent HDAC4 inhibitors for gliomas. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Figure 1

12 pages, 3477 KiB  
Article
HDAC2 Regulates Glial Cell Activation in Ischemic Mouse Retina
by Mi Sun Sung, Hwan Heo, Gwang Hyeon Eom, So Young Kim, Helong Piao, Yue Guo and Sang Woo Park
Int. J. Mol. Sci. 2019, 20(20), 5159; https://doi.org/10.3390/ijms20205159 - 17 Oct 2019
Cited by 16 | Viewed by 2901
Abstract
The current study was undertaken to investigate whether histone deacetylases (HDACs) can modulate the viability of retinal ganglion cells (RGCs) and the activity of glial cells in a mouse model of retinal ischemia-reperfusion (IR) injury. C57BL/6J mice were subjected to constant elevation of [...] Read more.
The current study was undertaken to investigate whether histone deacetylases (HDACs) can modulate the viability of retinal ganglion cells (RGCs) and the activity of glial cells in a mouse model of retinal ischemia-reperfusion (IR) injury. C57BL/6J mice were subjected to constant elevation of intraocular pressure for 60 min to induce retinal IR injury. Expression of macroglial and microglial cell markers (GFAP and Iba1), hypoxia inducing factor (HIF)-1α, and histone acetylation was analyzed after IR injury. To investigate the role of HDACs in the activation of glial cells, overexpression of HDAC1 and HDAC2 isoforms was performed. To determine the effect of HDAC inhibition on RGC survival, trichostatin-A (TSA, 2.5 mg/kg) was injected intraperitoneally. After IR injury, retinal GFAP, Iba1, and HIF-1α were upregulated. Conversely, retinal histone acetylation was downregulated. Notably, adenoviral-induced overexpression of HDAC2 enhanced glial activation following IR injury, whereas overexpression of HDAC1 did not significantly affect glial activation. TSA treatment significantly increased RGC survival after IR injury. Our results suggest that increased activity of HDAC2 is closely related to glial activation in a mouse model of retinal IR injury and inhibition of HDACs by TSA showed neuroprotective potential in retinas with IR injuries. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1135 KiB  
Review
Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia
by Sena Kim, Srikanth Santhanam, Sora Lim and Jaebok Choi
Int. J. Mol. Sci. 2020, 21(12), 4281; https://doi.org/10.3390/ijms21124281 - 16 Jun 2020
Cited by 9 | Viewed by 4136
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main therapeutic strategy for patients with both malignant and nonmalignant disorders. The therapeutic benefits of allo-HSCT in malignant disorders are primarily derived from the graft-versus-leukemia (GvL) effect, in which T cells in the donor graft [...] Read more.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main therapeutic strategy for patients with both malignant and nonmalignant disorders. The therapeutic benefits of allo-HSCT in malignant disorders are primarily derived from the graft-versus-leukemia (GvL) effect, in which T cells in the donor graft recognize and eradicate residual malignant cells. However, the same donor T cells can also recognize normal host tissues as foreign, leading to the development of graft-versus-host disease (GvHD), which is difficult to separate from GvL and is the most frequent and serious complication following allo-HSCT. Inhibition of donor T cell toxicity helps in reducing GvHD but also restricts GvL activity. Therefore, developing a novel therapeutic strategy that selectively suppresses GvHD without affecting GvL is essential. Recent studies have shown that inhibition of histone deacetylases (HDACs) not only inhibits the growth of tumor cells but also regulates the cytotoxic activity of T cells. Here, we compile the known therapeutic potential of HDAC inhibitors in preventing several stages of GvHD pathogenesis. Furthermore, we will also review the current clinical features of HDAC inhibitors in preventing and treating GvHD as well as maintaining GvL. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Figure 1

18 pages, 710 KiB  
Review
The Role of Histone Acetylation and the Microbiome in Phytochemical Efficacy for Cardiovascular Diseases
by Levi W. Evans, Maheshi Athukorala, Kristina Martinez-Guryn and Bradley S. Ferguson
Int. J. Mol. Sci. 2020, 21(11), 4006; https://doi.org/10.3390/ijms21114006 - 03 Jun 2020
Cited by 10 | Viewed by 3578
Abstract
Cardiovascular diseases (CVD) are the main cause of death worldwide and create a substantial financial burden. Emerging studies have begun to focus on epigenetic targets and re-establishing healthy gut microbes as therapeutic options for the treatment and prevention of CVD. Phytochemicals, commonly found [...] Read more.
Cardiovascular diseases (CVD) are the main cause of death worldwide and create a substantial financial burden. Emerging studies have begun to focus on epigenetic targets and re-establishing healthy gut microbes as therapeutic options for the treatment and prevention of CVD. Phytochemicals, commonly found in fruits and vegetables, have been shown to exert a protective effect against CVD, though their mechanisms of action remain incompletely understood. Of interest, phytochemicals such as curcumin, resveratrol and epigallocatechin gallate (EGCG) have been shown to regulate both histone acetylation and microbiome re-composition. The purpose of this review is to highlight the microbiome–epigenome axis as a therapeutic target for food bioactives in the prevention and/or treatment of CVD. Specifically, we will discuss studies that highlight how the three phytochemicals above alter histone acetylation leading to global changes in gene expression and CVD protection. Then, we will expand upon these phytochemicals to discuss the impact of phytochemical–microbiome–histone acetylation interaction in CVD. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Figure 1

21 pages, 1199 KiB  
Review
Histone Deacetylation Inhibitors as Modulators of Regulatory T Cells
by Andreas von Knethen, Ulrike Heinicke, Andreas Weigert, Kai Zacharowski and Bernhard Brüne
Int. J. Mol. Sci. 2020, 21(7), 2356; https://doi.org/10.3390/ijms21072356 - 29 Mar 2020
Cited by 32 | Viewed by 5691
Abstract
Regulatory T cells (Tregs) are important mediators of immunological self-tolerance and homeostasis. Being cluster of differentiation 4+Forkhead box protein3+ (CD4+FOXP3+), these cells are a subset of CD4+ T lymphocytes and can originate from [...] Read more.
Regulatory T cells (Tregs) are important mediators of immunological self-tolerance and homeostasis. Being cluster of differentiation 4+Forkhead box protein3+ (CD4+FOXP3+), these cells are a subset of CD4+ T lymphocytes and can originate from the thymus (tTregs) or from the periphery (pTregs). The malfunction of CD4+ Tregs is associated with autoimmune responses such as rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (T1D), inflammatory bowel diseases (IBD), psoriasis, systemic lupus erythematosus (SLE), and transplant rejection. Recent evidence supports an opposed role in sepsis. Therefore, maintaining functional Tregs is considered as a therapy regimen to prevent autoimmunity and allograft rejection, whereas blocking Treg differentiation might be favorable in sepsis patients. It has been shown that Tregs can be generated from conventional naïve T cells, called iTregs, due to their induced differentiation. Moreover, Tregs can be effectively expanded in vitro based on blood-derived tTregs. Taking into consideration that the suppressive role of Tregs has been mainly attributed to the expression and function of the transcription factor Foxp3, modulating its expression and binding to the promoter regions of target genes by altering the chromatin histone acetylation state may turn out beneficial. Hence, we discuss the role of histone deacetylation inhibitors as epigenetic modulators of Tregs in this review in detail. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Graphical abstract

18 pages, 2479 KiB  
Review
FcεRI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions
by Misun Kim, Yoojung Kwon, Hyun Suk Jung, Youngmi Kim and Dooil Jeoung
Int. J. Mol. Sci. 2019, 20(19), 4964; https://doi.org/10.3390/ijms20194964 - 08 Oct 2019
Cited by 10 | Viewed by 5214
Abstract
Anaphylaxis is an acute and life-threatening systemic reaction. Food, drug, aero-allergen and insect sting are known to induce anaphylaxis. Mast cells and basophils are known to mediate Immunoglobulin E (IgE)-dependent anaphylaxis, while macrophages, neutrophils and basophils mediate non IgE-dependent anaphylaxis. Histone deacetylases (HDACs) [...] Read more.
Anaphylaxis is an acute and life-threatening systemic reaction. Food, drug, aero-allergen and insect sting are known to induce anaphylaxis. Mast cells and basophils are known to mediate Immunoglobulin E (IgE)-dependent anaphylaxis, while macrophages, neutrophils and basophils mediate non IgE-dependent anaphylaxis. Histone deacetylases (HDACs) play various roles in biological processes by deacetylating histones and non-histones proteins. HDAC inhibitors can increase the acetylation of target proteins and affect various inflammatory diseases such as cancers and allergic diseases. HDAC3, a class I HDAC, is known to act as epigenetic and transcriptional regulators. It has been shown that HDAC3 can interact with the high-affinity Immunoglobulin E receptor (FcεRI), to mediate passive anaphylaxis and cellular interactions during passive anaphylaxis. Effects of HDAC3 on anaphylaxis, cellular interactions involving mast cells and macrophages during anaphylaxis, and any tumorigenic potential of cancer cells enhanced by mast cells will be discussed in this review. Roles of microRNAs that form negative feedback loops with hallmarks of anaphylaxis such as HDAC3 in anaphylaxis and cellular interactions will also be discussed. The roles of MCP1 regulated by HDAC3 in cellular interactions during anaphylaxis are discussed. Roles of exosomes in cellular interactions mediated by HDAC3 during anaphylaxis are also discussed. Thus, review might provide clues for development of drugs targeting passive anaphylaxis. Full article
(This article belongs to the Special Issue Histone Deacetylase Inhibitors in Health and Disease II)
Show Figures

Graphical abstract

Back to TopTop